Pfizer’s Leads IGF-1 Inhibitor Pack In Phase III For NSCLC
This article was originally published in The Pink Sheet Daily
Executive Summary
Pathway still holds mystery, global lead clinician tells “The Pink Sheet” DAILY.
You may also be interested in...
Lilly’s ImClone Buy Adds Oncology Candidates And Pipeline Pressures
Eli Lilly announced Oct. 6 that it is acquiring ImClone for $6.5 billion, confirming rumors that had been circulating since the middle of the previous week. The central question now is whether Lilly can turn the buyout into a win for shareholders
Lilly’s ImClone Buy Adds Oncology Candidates And Pipeline Pressures
Eli Lilly announced Oct. 6 that it is acquiring ImClone for $6.5 billion, confirming rumors that had been circulating since the middle of the previous week. The central question now is whether Lilly can turn the buyout into a win for shareholders
Pfizer Plots Major Phase III Push
Lipitor soon to fade; company faces “challenge of a lifetime,” says R&D president.